Hemogenyx Pharmaceuticals PLC US Subsidiary Change of Name
July 10 2020 - 8:00AM
RNS Non-Regulatory
TIDMHEMO
Hemogenyx Pharmaceuticals PLC
10 July 2020
10 July 2020
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
U.S. Subsidiary Change of Name
Hemogenyx Pharmaceuticals plc is pleased to announce that its
U.S. subsidiary will be renamed Hemogenyx Pharmaceuticals LLC in
order to align the Company's names across entities and countries,
and should always be referred to as Hemogenyx Pharmaceuticals
instead of Hemogenyx by itself. The company will continue to
conduct preclinical and clinical stage research and development
activities to develop its own products and therapies, including
therapies and treatments for blood and autoimmune diseases and
viral infections. Hemogenyx Pharmaceuticals LLC will remain located
at its state-of-the-art research facility in New York City.
Enquiries:
Hemogenyx Pharmaceuticals plc https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive
Officer & Co-Founder headquarters@hemogenyx.com
Peter Redmond, Director
Tel: +44 (0)20 3470
SP Angel Corporate Finance LLP 0470
Matthew Johnson, Vadim Alexandre,
Soltan Tagiev
Tel: +44 (0)20 7469
Peterhouse Capital Limited 0930
Lucy Williams, Duncan Vasey, Charles
Goodfellow
US Media enquiries Tel: +1 (323) 646-3249
Lowell Goodman lowell@corbomitecomms.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAUPUMUMUPUPGM
(END) Dow Jones Newswires
July 10, 2020 08:00 ET (12:00 GMT)
Silver Falcon (LSE:SILF)
Historical Stock Chart
From Jul 2024 to Aug 2024
Silver Falcon (LSE:SILF)
Historical Stock Chart
From Aug 2023 to Aug 2024